Kissei Pharmaceutical Co Ltd (4547):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Kissei Pharmaceutical Co Ltd (4547) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11504
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:30
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:日本
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Kissei Pharmaceutical Co Ltd (Kissei) discovers, manufactures and sells a range of innovative pharmaceutical products and develops. The company’s pharmaceutical products include urological medicine, metabolic endocrinology medicine, drugs for kidney and dialysis department, drug for obstetrics and gynecology and ophthalmic medicine. It also develops and sells health foods including protein controlled food, energy supply food, calorie controlled food and elderly controlled food. Kissei’s research and development (R&D) activities focus on the development of novel drugs, improve existing drugs and provide superior drugs to people worldwide. The company has sales offices across Japan and an overseas subsidiary in New Jersey, the US. Kissei is headquartered in Matsumoto, Japan.

Kissei Pharmaceutical Co Ltd (4547) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Kissei Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Kissei Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Kissei Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Kissei Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Kissei Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Kissei Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Kissei Pharma Enters into Agreement with Kyorin Pharma 10
Kissei Pharma Enters into Co-Development Agreement with Ajinomoto Pharma 11
Kissei Pharma Enters into Co-Development Agreement with Alteogen for Biosimilars 12
Kissei Pharma Enters Into Co-Development Agreement With JCR Pharma 13
Licensing Agreements 14
Kissei Pharma Enters into Licensing Agreement with Rigel Pharma 14
Kissei Pharma Enters into Licensing Agreement with Vifor Fresenius Medical Care Renal Pharma 15
ObsEva Enters into Licensing Agreement with Kissei Pharma 16
Kissei Pharmaceutical Co Ltd – Key Competitors 17
Kissei Pharmaceutical Co Ltd – Key Employees 18
Kissei Pharmaceutical Co Ltd – Locations And Subsidiaries 19
Head Office 19
Other Locations & Subsidiaries 19
Recent Developments 20
Corporate Communications 20
Apr 23, 2018: Kissei Announces New President and COO 20
Clinical Trials 22
Jun 18, 2018: ObsEva Achieves Primary and Secondary Endpoints for EDELWEISS Phase 2b Clinical Trial of Linzagolix (OBE2109) in Women with Endometriosis 22
Jun 15, 2018: ObsEva to Hold Investor Call to Announce Topline Results of the EDELWEISS Phase 2b Clinical Trial of Linzagolix (OBE2109) in Women with Endometriosis-Associated Pain on Monday June 18, 2018 24
Apr 23, 2018: ObsEva Announces Upcoming Presentations Related to its Endometriosis and Uterine Fibroid Development Programs with its Novel Oral GnRH Receptor Antagonist OBE2109 (KLH-2109) 25
Nov 07, 2017: ObsEva Announces the Completion of Patient Recruitment in the EDELWEISS Phase 2b Clinical Trial of OBE2109 for the Treatment of Endometriosis 26
Jun 07, 2017: ObsEva Announces the Completion of a Phase 1 PK/PD Clinical Trial Evaluating Different Doses of OBE2109 and Add-Back Therapy 27
Apr 25, 2017: ObsEva Initiates Phase 3 Clinical Program for OBE2109 in Uterine Fibroids 29
Appendix 30
Methodology 30
About GlobalData 30
Contact Us 30
Disclaimer 30

List of Tables
Kissei Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Kissei Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Kissei Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Kissei Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Kissei Pharmaceutical Co Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
Kissei Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Kissei Pharma Enters into Agreement with Kyorin Pharma 10
Kissei Pharma Enters into Co-Development Agreement with Ajinomoto Pharma 11
Kissei Pharma Enters into Co-Development Agreement with Alteogen for Biosimilars 12
Kissei Pharma Enters Into Co-Development Agreement With JCR Pharma 13
Kissei Pharma Enters into Licensing Agreement with Rigel Pharma 14
Kissei Pharma Enters into Licensing Agreement with Vifor Fresenius Medical Care Renal Pharma 15
ObsEva Enters into Licensing Agreement with Kissei Pharma 16
Kissei Pharmaceutical Co Ltd, Key Competitors 17
Kissei Pharmaceutical Co Ltd, Key Employees 18
Kissei Pharmaceutical Co Ltd, Other Locations 19
Kissei Pharmaceutical Co Ltd, Subsidiaries 19

List of Figures
Kissei Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Kissei Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Kissei Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Kissei Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Kissei Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Kissei Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Kissei Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Kissei Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Kissei Pharmaceutical Co Ltd (4547):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Graftys SA-医療機器分野:企業M&A・提携分析
    Summary Graftys SA (Graftys) is a medical device company that focuses on the development, manufacture and commercialization of synthetic bioactive orthopedic biomaterials. It provides a wide range of synthetic and bioresorbable bone graft substitutes and other cement products. The company’s products …
  • North China Pharmaceutical Group Corp-製薬・医療分野:企業M&A・提携分析
    Summary North China Pharmaceutical Group Corp (NCPC) is a healthcare products provider that manufactures and distributes antibiotic bulks and formulations, vitamins and nutrition products. The company’s products comprise antibiotics, penicillin, amoxicillin, streptomycin sulfate, cefradine, 7-ADCA, …
  • ConforMIS Inc (CFMS):医療機器:M&Aディール及び事業提携情報
    Summary ConforMIS Inc (ConforMIS) is a medical technology company that manufactures, develops, and markets joint replacement implants. The company’s knee replacement implant products include iTotal CR a cruciate-retaining product, iTotal PS a posterior cruciate ligament substituting product, and iDu …
  • Dimension Data Holdings Plc:企業の戦略的SWOT分析
    Dimension Data Holdings Plc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major product …
  • Gentex Corporation:企業の戦略・SWOT・財務情報
    Gentex Corporation - Strategy, SWOT and Corporate Finance Report Summary Gentex Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Mercury NZ:企業の戦略・SWOT・財務情報
    Mercury NZ - Strategy, SWOT and Corporate Finance Report Summary Mercury NZ - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Odebrecht S.A.:戦略・SWOT・企業財務分析
    Odebrecht S.A. - Strategy, SWOT and Corporate Finance Report Summary Odebrecht S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • A&W Food Services of Canada Inc:企業の戦略・SWOT・財務情報
    A&W Food Services of Canada Inc - Strategy, SWOT and Corporate Finance Report Summary A&W Food Services of Canada Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Nobel Biocare Services AG:企業の戦略的SWOT分析
    Nobel Biocare Services AG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Alkane Energy Plc:石油・ガス:M&Aディール及び事業提携情報
    Summary Alkane Energy Plc (Alkane Energy), a subsidiary of Basalt Infrastructure Partners LLP, is a diversified company. The company power from coal mine methane and natural gas facilities. It has natural gas, coal bed methane, coal mine methane and shale gas. Alkane Energy design, builds and operat …
  • Rheinmetall AG (RHM):企業の財務・戦略的SWOT分析
    Rheinmetall AG (RHM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • mixi, Inc.:企業の戦略・SWOT・財務情報
    mixi, Inc. - Strategy, SWOT and Corporate Finance Report Summary mixi, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Pets at Home Limited (PETS):企業の財務・戦略的SWOT分析
    Pets at Home Limited (PETS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • FMT Aircraft Gate Support Systems AB:企業の戦略・SWOT・財務情報
    FMT Aircraft Gate Support Systems AB - Strategy, SWOT and Corporate Finance Report Summary FMT Aircraft Gate Support Systems AB - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysi …
  • SymBio Pharmaceuticals Ltd (4582):製薬・医療:M&Aディール及び事業提携情報
    Summary SymBio Pharmaceuticals Ltd (SymBio) is a biopharmaceutical company that develops and markets anti-cancer drug candidates. The company develops SyB drugs, treakisym and rigosertib, among others. It offers business development services in areas of oncology, hematology and pain-management areas …
  • Synthetic Biologics Inc (SYN):製薬・医療:M&Aディール及び事業提携情報
    Summary Synthetic Biologics Inc (Synthetic Biologics), formerly Adeona Pharmaceuticals Inc is a clinical company that develops novel therapeutics to treat gut microbiome. The company’s pipeline products include SYN-004 and SYN-010. Its SYN-010 is a proprietary, modified-release formulation which is …
  • Ingka Holding B.V.:企業の戦略・SWOT・財務情報
    Ingka Holding B.V. - Strategy, SWOT and Corporate Finance Report Summary Ingka Holding B.V. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Icade SA:企業のM&A・事業提携・投資動向
    Icade SA - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Icade SA Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital …
  • Australian Vintage Limited:企業の戦略・SWOT・財務分析
    Australian Vintage Limited - Strategy, SWOT and Corporate Finance Report Summary Australian Vintage Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Commercial Bank Of Kuwait Sak:企業の戦略・SWOT・財務分析
    Commercial Bank Of Kuwait Sak - Strategy, SWOT and Corporate Finance Report Summary Commercial Bank Of Kuwait Sak - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆